AMG 436 Clinical Trials (2026): 1 Studies for Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: .

1 AMG 436 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)) and 464 total planned enrollment. 1 AMG 436 clinical trial is actively recruiting at 5 U.S. sites across 5 states. Most recent activity: NCT07403721 (Jun 2028).

Where to Participate: All AMG 436 Trial Sites in the U.S. (5 sites across 5 states)

Every actively recruiting AMG 436trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

StateFacilityCityTrialMap
CACity of Hope Orange County Lennar Foundation Cancer CenterIrvine92618NCT07403721Map
ILMidwestern Regional Medical Center dba City of Hope ChicagoZion60099NCT07403721Map
MENew England Cancer SpecialistsWestbrook04092NCT07403721Map
TNTennessee Oncology PLLCNashville37203NCT07403721Map
TXNext Oncology - DallasIrving75039NCT07403721Map

AMG 436 clinical trials at a glance: phase × recruitment status

PhaserecruitingTotal
P111

Recruiting AMG 436 clinical trials (1)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT IDTitlePhaseIndicationEnrollmentStarted
NCT07403721AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid TumorsP1Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)464Apr 2026

All AMG 436 trials (1)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT IDAcronymTitlePhaseStatusEnrollmentSponsorStarted
NCT07403721AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid TumorsP1recruiting464AmgenApr 2026

AMG 436 clinical trials: frequently asked questions

How many AMG 436 clinical trials are there?
1 AMG 436 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
Are AMG 436 clinical trials recruiting in 2026?
Yes — 1 AMG 436 trial is actively recruiting in 2026, with 5 U.S. sites across 5 states. See the recruiting trials and the per-state site list further down this page.
What conditions is AMG 436 being studied for?
AMG 436 is being studied for Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR). The trials are grouped by indication on this page.
What phase is AMG 436 in?
AMG 436 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors AMG 436 clinical trials?
The lead sponsor across the most AMG 436 trials is Amgen. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming AMG 436as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed .

Related pages on Hipa.ai: